Moderna, Inc. (NASDAQ:MRNA) Expected to Earn Q3 2025 Earnings of $1.30 Per Share

Moderna, Inc. (NASDAQ:MRNA) – Equities research analysts at William Blair lifted their Q3 2025 EPS estimates for Moderna in a report released on Thursday, May 2nd. William Blair analyst M. Minter now anticipates that the company will earn $1.30 per share for the quarter, up from their prior estimate of $1.25. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Moderna’s current full-year earnings is ($7.47) per share. William Blair also issued estimates for Moderna’s Q4 2025 earnings at $1.36 EPS, FY2026 earnings at ($0.72) EPS and FY2027 earnings at $3.16 EPS.

A number of other equities research analysts have also weighed in on MRNA. Royal Bank of Canada upped their target price on shares of Moderna from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Friday. Canaccord Genuity Group increased their price objective on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research note on Friday. HSBC reiterated a “reduce” rating and issued a $86.00 price objective (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Jefferies Financial Group reiterated a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Thursday. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $129.55.

Moderna Trading Down 0.5 %

MRNA opened at $125.00 on Monday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.36. Moderna has a fifty-two week low of $62.55 and a fifty-two week high of $142.79. The firm has a market capitalization of $47.86 billion, a PE ratio of -7.98 and a beta of 1.57. The company’s 50-day moving average is $105.05 and its 200 day moving average is $94.48.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. During the same quarter in the prior year, the business posted $0.19 EPS. The firm’s revenue was down 91.0% compared to the same quarter last year.

Insider Buying and Selling

In related news, President Stephen Hoge sold 2,388 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the transaction, the president now directly owns 1,515,898 shares of the company’s stock, valued at approximately $143,358,473.86. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Moderna news, insider Shannon Thyme Klinger sold 670 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $63,361.90. Following the sale, the insider now directly owns 8,557 shares in the company, valued at approximately $809,235.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Stephen Hoge sold 2,388 shares of the stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the completion of the sale, the president now owns 1,515,898 shares in the company, valued at $143,358,473.86. The disclosure for this sale can be found here. In the last ninety days, insiders sold 139,954 shares of company stock valued at $14,822,576. Company insiders own 15.70% of the company’s stock.

Institutional Trading of Moderna

Several institutional investors and hedge funds have recently bought and sold shares of MRNA. Allworth Financial LP raised its position in shares of Moderna by 6.5% during the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock valued at $165,000 after buying an additional 101 shares in the last quarter. TIAA Trust National Association raised its position in shares of Moderna by 2.3% during the 4th quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after buying an additional 102 shares in the last quarter. Principle Wealth Partners LLC raised its position in shares of Moderna by 4.3% during the 1st quarter. Principle Wealth Partners LLC now owns 2,497 shares of the company’s stock valued at $266,000 after buying an additional 102 shares in the last quarter. Sound Income Strategies LLC raised its position in shares of Moderna by 17.8% during the 4th quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock valued at $76,000 after buying an additional 115 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in shares of Moderna by 32.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after buying an additional 116 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.